|
Over 400 thought leaders from 200+ organizations,
representing 21 countries, gathered at the Biomarker World Congress 2009
(May 27-29 in Philadelphia) to discuss the biomarker impact on
Personalized Medicine, Clinical Pharmacology, Translational Medicine,
Molecular Diagnostics, Safety Assessment, Clinical Trials, Assay
Development, Go/No-Go Decision Making and Oncology in Drug &
Diagnostics. The level of energy and participation reflected the booming
interest in this field.
CHI would like to thank the scientific advisors, sponsors, and all of
the participants for making this meeting another Biomarker & Diagnostic
Series success!
Mark your Calendar for 2010 Biomarker World Congress 2010, May
4-6, 2010, Philadelphia, Pennsylvania
|
Pre-Conference Events:
-
Executive ThinkTank: Collaborations, Consortia, and Funding
Opportunities in Biomarker Development
-
Short Course: Fit-for-Purpose Biomarker Assay Development &
Validation
-
Workshop: Biomarkers for Cancer Drug Development
|
|
Attention Biomarker World Congress 2009 Attendees
Registered attendees to the Biomarker
World Congress 2009 will receive 20% of any Biomarker Web Symposia
Click here for more information about the
Biomarker
Web Symposia
|
|
|
Comprehensive Coverage of Biomarkers in:
-
Personalized Medicine
-
Clinical Pharmacology
-
Translational Medicine
-
Molecular Diagnostics
-
Safety Assessment
-
Clinical Trials
-
Assay Development
-
Biomarker Qualification
-
Oncology Drugs & Diagnostics
|
New for 2009
The Biomarker Bridge
Join today and become a member of the
Biomarker Bridge Community Network
Become a member of the Biomarker Bridge - an interactive
community network for pharmaceutical, clinical and IT
professionals who are interested in gaining and sharing
knowledge about technologies, research, and regulatory issues
around life science.
Click here to view more information about the
Biomarker Bridge. |
|
|
Featured Speakers
Klaus Lindpaintner
Head, Medical
Genomics; VP,
Research, Roche |
Giora Feuerstein
AVP & Head Discovery,
Translational
Medicine, Wyeth |
Nicholas C. Dracopoli
VP, Biomarkers
Centocor,
Johnson & Johnson |
David Wholley,
Director, Biomarkers
Consortium,
Foundation for
the NIH |
Lawrence J. Lesko
Director, Clinical
Pharmacology
CDER, FDA |
 C. Thomas Caskey
EVP, Molecular
Medicine and Genetics, Univ. of Texas Health Science Center |
Geert Kolvenbag
Global Product VP,
Oncology, AstraZeneca |
 Francois
Legay
Global Head, Marker Assays, Novartis |
Robert S. Epstein
SVP & Chief Medical Officer, Medco
Health Solutions |
 Phil Hewitt
Head, Molecular
Toxicology, Merck |
|
|
The Intro-Net offers you the opportunity to set up meetings
with selected attendees Before, during and after this
conference, allowing you to connect to the key people You want
to meet. This online system was designed with you privacy in
mind and is Only available to registered session attendees of
this event. Attendees will receive
more information on accessing the Intro-Net in the weeks leading
up to the event! |
|
|
|
For more information, please contact:
Julia Boguslavsky, Executive Director, Conferences
E-mail: juliab@healthtech.com
For sponsorship information, please contact:
Ilana Schwartz, Business Development
Phone: 781-972-5457; E-mail: ischwartz@healthtech.com
|
THE LARGEST INTERNATIONAL EVENT DEDICATED TO ALL AREAS OF DRUG AND DIAGNOSTIC
DEVELOPMENT IMPACTED BY BIOMARKERS…
 |
|
